U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C65H89N9O25
Molecular Weight 1396.4475
Optical Activity UNSPECIFIED
Defined Stereocenters 14 / 14
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of L-377202

SMILES

COC1=CC=CC2=C1C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]5C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H]6C[C@@H](O)CN6C(=O)CCCC(O)=O)C7CCCCC7)[C@H](O)[C@H](C)O5)C(=O)CO)C(O)=C3C2=O

InChI

InChIKey=CZXGBIFEWYVYJY-NPLULESDSA-N
InChI=1S/C65H89N9O25/c1-28(2)19-37(60(91)69-36-21-47(98-30(4)53(36)84)99-42-23-65(96,43(79)27-77)22-34-49(42)57(88)51-50(55(34)86)54(85)33-13-9-14-41(97-5)48(33)56(51)87)70-61(92)38(25-75)72-59(90)35(17-18-44(66)80)68-64(95)52(31-11-7-6-8-12-31)73-62(93)39(26-76)71-58(89)29(3)67-63(94)40-20-32(78)24-74(40)45(81)15-10-16-46(82)83/h9,13-14,28-32,35-40,42,47,52-53,75-78,84,86,88,96H,6-8,10-12,15-27H2,1-5H3,(H2,66,80)(H,67,94)(H,68,95)(H,69,91)(H,70,92)(H,71,89)(H,72,90)(H,73,93)(H,82,83)/t29-,30-,32+,35-,36-,37-,38-,39-,40-,42-,47-,52-,53+,65-/m0/s1

HIDE SMILES / InChI

Molecular Formula C65H89N9O25
Molecular Weight 1396.4475
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 14 / 14
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Fri Dec 15 15:45:04 GMT 2023
Edited
by admin
on Fri Dec 15 15:45:04 GMT 2023
Record UNII
VDXVABRQTV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
L-377202
Code English
5-((2S,4R)-2-(((1S)-2-(((1S)-2-(((1S)-2-(((1S)-4-AMINO-1-(((1S)-1-(HYDROXYMETHYL)-2-(((1S)-1-(((2S,3S,4S,6R)-3-HYDROXY-2-METHYL-6-(((1S,3S)-3,5,12-TRIHYDROXY-3-(2-HYDROXYACETYL)-10-METHOXY-6,11-DIOXO-2,4-DIHYDRO-1H-TETRACEN-1-YL)OXY)TETRAHYDROPYRAN-4-YL)
Systematic Name English
L-377202-000H
Code English
5,12-NAPHTHACENEDIONE, 10-((3-(((4R)-1-(4-CARBOXY-1-OXOBUTYL)-4-HYDROXY-L-PROLYL-L-ALANYL-L-SERYL-(2S)-2-CYCLOHEXYLGLYCYL-L-GLUTAMINYL-L-SERYL-L-LEUCYL)AMINO)-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(2-HYD
Systematic Name English
Code System Code Type Description
PUBCHEM
9855284
Created by admin on Fri Dec 15 15:45:04 GMT 2023 , Edited by admin on Fri Dec 15 15:45:04 GMT 2023
PRIMARY
CAS
207395-85-5
Created by admin on Fri Dec 15 15:45:04 GMT 2023 , Edited by admin on Fri Dec 15 15:45:04 GMT 2023
PRIMARY
NCI_THESAURUS
C1853
Created by admin on Fri Dec 15 15:45:04 GMT 2023 , Edited by admin on Fri Dec 15 15:45:04 GMT 2023
PRIMARY
FDA UNII
VDXVABRQTV
Created by admin on Fri Dec 15 15:45:04 GMT 2023 , Edited by admin on Fri Dec 15 15:45:04 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY
L-377,202 was approximately 15 times more effective than was conventional doxorubicin at inhibiting the growth of human prostate cancer tumors in nude mice when both drugs were used at their maximally tolerated doses.
ACTIVE MOIETY
For each cycle, L-377202 will be administered as a 30-minute infusion every 3 weeks. The starting dose will be 20 mg/m2/week. Doses will be doubled until a patient experiences a greater than or equal to Grade 2 toxicity.
ACTIVE MOIETY
A prodrug in which a peptide is covalently conjugated with the anthracycline antineoplastic antibiotic doxorubicin.